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Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI
delivery, particularly for COPD patients unable to use hand-held devices easily or correctly.
The long-acting b2-agonist, formoterol fumarate, is differentiated by its onset of
significant bronchodilation within 5min of administration.
In a randomized, double-blind, double-dummy trial, COPD subjects (n ¼ 351, mean forced
expiratory volume FEV1 ¼ 1.3 L, 44% predicted) received nebulized formoterol fumarate
(PerforomistTM inhalation solution; FFIS 20 mg) or DPI (Foradils Aerolizers; FA 12 mg), or
placebo twice daily for 12 weeks. Efficacy was assessed with 12-h pulmonary function
tests, and quality of life was assessed before and after treatment with the St. George’s
Respiratory Questionnaire (SGRQ).
At the 12-week endpoint, FFIS significantly increased FEV1 AUC0–12h relative to placebo
(po0.0001). No evidence of tachyphylaxis was observed as indicated by maintained FEV1
AUC and reduced rescue albuterol use throughout treatment. FFIS also significantly
increased peak FEV1, trough FEV1, and standardized FVC AUC0–12h compared with placebo.
SGRQ assessment at Week 12 demonstrated significant and clinically meaningful
improvements in total score (FFIS vs placebo, 4.9, p ¼ 0.0067), symptom, and impact
scores. No significant differences in efficacy were observed between the two active
treatments. Drug related AEs in the FFIS arm with a frequencyX1% and exceeding placebo
were dry mouth, nausea, and insomnia.Elsevier Ltd. All rights reserved.




N.J. Gross et al.190Nebulized FFIS provided significant improvement in respiratory status and quality of life in
subjects with COPD relative to placebo and was well tolerated. The efficacy and safety
profile of FFIS was comparable to FA DPI.
& 2007 Elsevier Ltd. All rights reserved.Introduction
While metered dose inhalers (MDIs) and dry powder inhalers
(DPIs) are efficient, convenient, and economical, nebulized
treatments are an important alternative for patients who
are unable to use MDIs and DPIs easily or correctly, such as
patients with poor coordination, physical or visual impair-
ment, or very ill inpatients. Patients with chronic obstruc-
tive pulmonary disease (COPD) in particular, being elderly,
often have these limitations. In addition, many COPD
patients or their caregivers feel they obtain more benefit
from nebulized treatments.1,2 Guidelines have been devel-
oped to ensure optimal device selection and use of
nebulized treatment3,4 and have concluded that equally
efficacious treatment can be provided with proper device
use and training.3
Long-acting b-agonists (LABAs) are a key step in the
algorithm for regular disease management in moderate-to-
severe COPD patients.5 The current study evaluated a new
nebulized formulation of the LABA, formoterol fumarate, in
COPD. Formoterol has a rapid onset of action, comparable to
that of albuterol and superior to salmeterol,6,7 along with
greater selectivity for b2-adrenoceptors than albuterol
8 and
prolonged duration of action allowing for twice-daily
dosing.8 The effectiveness of formoterol as maintenance
treatment for COPD patients was demonstrated in several
controlled trials using DPI delivery.9–11 Its tolerability has
been demonstrated with long-term global use in treating
airways disease and 10 million patient-years of use12 in the
United States.
Dose–response studies indicated a nebulized dose of 20 mg
formoterol fumarate inhalation solution (FFIS) was compar-
able to the marketed 12 mg dose of formoterol fumarate DPI
(Foradils) (unpublished). We now present the results of a
12-week, randomized, placebo-controlled, double-blind,
double-dummy study comparing the efficacy and safety of
the nebulized formulation to formoterol DPI in patients with
moderate-to-severe COPD.Methods
Subjects
Study participants were outpatients aged X40 years who
gave written informed consent. Inclusion criteria required a
current or prior history ofX10 pack-years cigarette smoking
and a diagnosis of COPD, including persistent cough, sputum
production, and/or shortness of breath on effort. Subjects
were included if the post-bronchodilator forced expiratory
volume in 1 s (FEV1) wasX30% ando70% predicted normal13
and FEV1/forced vital capacity (FVC) ratio o0.70.
Subjects were excluded if they had a current or past
diagnosis of asthma, a respiratory tract infection or acuteexacerbation of COPD within the past month, required long-
term oxygen therapy, had an electrocardiographic QTc
interval 40.46 s, recent myocardial infarction, or other
clinically significant comorbidities. Inhaled or oral corticos-
teroids (equivalent to prednisone p10mg daily) were
permitted if the dose was stable for the previous month.
Study design
The study was a multicenter, double-blind, randomized,
parallel-group, active- and placebo-controlled study con-
ducted at 38 centers in the United States (clinicaltrials.gov
NCT00215436). Approval was obtained by the Institutional
Review Board for each center prior to patient recruitment;
the study was conducted in accordance with GCP and ICH
guidelines and the Declaration of Helsinki. Following screen-
ing, subjects entered a single-blind run-in period of 4–14
days, during which they received placebos matched to both
Aerolizers and nebulizer for twice daily (b.i.d.) adminis-
tration. Albuterol MDIs (90mg/puff) were provided as rescue
medication during screening and treatment periods of
the study.
Eligible subjects were randomized to 12 weeks of double-
blind, double-dummy treatment with FFIS (PerforomistTM
inhalation solution 20 mg/2mL, Dey, L.P., Napa, CA) deliv-
ered by the PARI LCs Plus jet nebulizer with PARI PRONEBs
compressor, formoterol fumarate DPI 12 mg (FA; Foradils
Aerolizers, Novartis Pharmaceuticals, East Hanover, NJ) or
placebo. Treatment via Aerolizers was administered first
and the post-dose time was measured from the conclusion of
nebulizer treatment.
Variables
Prior to entry and at study completion, subjects underwent
physical examination, medical history, laboratory evalua-
tions, Holter monitoring, and 12-lead ECG. Visits were
scheduled on the first day of study drug administration and
every 4 weeks thereafter. Quality of life (QoL) was measured
before the first dose of study medications and at study
completion using St. George’s Respiratory Questionnaire
(SGRQ).14,15 A study diary documented the daily use of
rescue and study medication.
Pulmonary function tests were performed using spirome-
try.13,16 The pre-dose baseline FEV1 on Day 1 was within 15%
of the screening pre-bronchodilator FEV1 and o70% pre-
dicted normal. Spirometry at Day 1 and Weeks 4, 8, and 12
was performed 30min prior to the morning dose, and at 5
and 30min, and 1, 2, 3, 6, 9, 12 h post-dose. Post-dose
spirometry began at the end of nebulization.
The primary outcome was standardized absolute FEV1
area under the curve (AUC) over 12 h following the morning
dose of study medication after 12 weeks of treatment.
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and FVC measurements on all visit days, peak FEV1 during
12 h, trough FEV1, rescue medication use, and SGRQ scores
on Day 1 and Week 12 for total and component (symptom,
activity, impact) scores.Statistical analysis
For the primary outcome, FEV1 AUC0–12, a standard devia-
tion of 0.400 L9 was assumed. A sample of 115 subjects per
treatment group ensured 90% power to detect a difference
of 0.172 L in standardized FEV1 AUC0–12 (two-sided a ¼ 0.05)
between FFIS and placebo.
Analysis of the primary efficacy variable was performed
with the modified intent-to-treat (ITT) and completer
populations using the last observation carried forward
(LOCF) method for subjects with missing values in the ITT
population. Primary efficacy analysis of the completer
population included subjects who received X1 dose of
study medication, had no major efficacy protocol violations,
and had pre-dose and hour 12 FEV1 measurements at the
Week 12 visit. The difference in treatment group least-
squares (LS) means was presented to make statistical
inferences. An analysis of covariance (ANCOVA) model was
used to estimate treatment differences for endpointsFigure 1 Subject disposition. FFIS: formoterol fumarate inhalationderived from spirometry and included fixed effects for
treatment and center; baseline values were a covariate.
An ANOVA model was used to test for treatment differ-
ences between mean average daily albuterol use at
each visit.Results
The study was conducted from March 2005 to September
2005. The disposition of study subjects is presented in
Figure 1. All subjects randomized to treatment (n ¼ 351)
received X1 dose of study medication and were included in
the ITT and safety populations. Fewer placebo- than active-
treated subjects completed the study; the most common
reason for discontinuation was adverse events.
Baseline demographics were similar across treatment
groups with no statistically significant differences (Table 1).
Pulmonary function was comparable among treatment
groups and characteristic of a moderate-to-severe COPD
population.
Inhaled corticosteroids (ICS) were used concomitantly by
approximately 20%, 23%, and 19% of FFIS-, FA-, and placebo-
treated subjects, respectively; whereas, oral corticosteroids
were used at least once during the trial by 6%, 10%, and 12%
of FFIS-, FA-, and placebo-treated subjects, respectively.solution 20 mg BID and FA: formoterol fumarate DPI 12 mg BID.
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Table 1 Baseline demographics and values of all randomized patients.
FFIS (n ¼ 123) FA (n ¼ 114) Placebo (n ¼ 114) Total (n ¼ 351)
Age (years), mean (S.D.) 61.8 (8.6) 63.0 (9.4) 63.5 (9.2) 62.8 (9.1)
Gender, n (%)
Male 71 (58) 61 (54) 65 (57) 197 (56)
Female 52 (42) 53 (46) 49 (43) 154 (44)
Current smoker, n (%) 60 (49) 61 (54) 61 (54) 182 (52)
Race, n (%)
Caucasian 108 (88) 95 (83) 98 (86) 301 (86)
Hispanic 4 (3) 6 (5) 3 (3) 13 (4)
Black 11 (9) 13 (11) 12 (10) 36 (10)
Asian 0 0 1 (1) 1 (0.3)
Other 0 0 0 0
Bronchodilator reversible, n (%) 71 (58) 73 (64) 58 (51) 202 (58)
Pre-bronchodilator % predicted
FEV1, mean (S.D.)
44.3 (11.5) 43.9 (11.6) 45.3 (13.2) 44.5 (12.1)
Baseline FEV1 (L), mean (S.D.)
Pre-bronchodilator 1.35 (0.46) 1.30 (0.40) 1.36 (0.50) 1.34 (0.45)
Post-bronchodilatory 1.51 (0.47) 1.49 (0.42) 1.51 (0.47) 1.50 (0.45)
Pre-bronchodilator FEV1/FVC,
mean (S.D.)
0.53 (0.10) 0.53 (0.10) 0.54 (0.10) 0.53 (0.10)
10% increase in FEV1 30min after inhaling two puffs of albuterol.
y30min after inhaling two puffs of albuterol.
Table 2 Baseline FEV1 and standardized FEV1 AUC0–12














































Baseline FEV1 ¼ Pre-bronchodilator FEV1 at Day 1, End-
point ¼ Week 12 or early termination (LOCF).
ypo0.0001 vs placebo, LS mean difference.
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The standardized absolute AUC0–12 for FEV1 measured over
12 h following the AM dose of study medication at Week 12
(or early termination) in the ITT population was significantly
improved in the FFIS group compared with placebo
(Table 2). The LS mean difference between FFIS and placebo
in the ITT and completer populations was 0.185 L (95% CI,
0.120–0.251, po0.0001) and 0.207 L (95% CI, 0.127–0.287,
po0.0001), respectively. FFIS FEV1 AUC0–12 improvements
seen on Day 1 were maintained at each subsequent visit,
demonstrating no decrease in response, i.e. tachyphylaxis,
over the 12-week treatment period (Table 2).
FFIS provided significant increases in FEV1 compared to
placebo at the first timepoint of 5min after dosing and at
every timepoint thereafter both at Day 1 and Week 12
(pp0.0007; Figure 2). FEV1 values at each timepoint at
Weeks 4 and 8 were also significantly greater for FFIS than
placebo (data not shown, pp0.0003).
Peak FEV1 remained higher in the FFIS group compared
to placebo throughout the study, with a LS mean difference
of 0.247 L at Week 12 (95% CI, 0.174–0.320, po0.0001;
Figure 3). Trough FEV1 values were also higher in the FFIS
group relative to placebo group at each visit (Figure 3). The
LS mean improvement in trough FEV1 compared with
placebo at Week 12 was 0.143 L (95% CI, 0.067–0.219,
p ¼ 0.0003). FFIS treatment was associated with higher
mean FVC AUC0–12 values compared with placebo at Day 1
and each subsequent visit (Figure 3). The LS meanimprovement in FVC AUC0–12 compared with placebo at
Week 12 was 0.341 L (95% CI, 0.191–0.491, po0.0001).
FFIS results for FEV1 AUC0–12, 12-h FEV1 measurements,
peak FEV1, trough FEV1, and FVC across all visits were
ARTICLE IN PRESS
Figure 2 Time course of mean FEV1 response after first dose
(Day 1) and 12 weeks of treatment in the ITT population. FFIS:
formoterol fumarate inhalation solution 20 mg BID and FA:
formoterol fumarate DPI 12mg BID. Data expressed as LS means
adjusted for baseline FEV1. LS mean difference at each
timepoint on Day 1 and Week 12: FFIS vs placebo pp0.0007
and FA vs placebo po0.05.
Figure 3 Mean peak and trough FEV1, and FVC AUC0–12 over 12
weeks of treatment. FFIS: formoterol fumarate inhalation
solution 20 mg BID and FA: formoterol fumarate DPI 12 mg BID.
LS mean difference at each visit: FFIS vs placebo pp0.0003 and
FA vs placebo pp0.007.
Figure 4 Change from baseline in SGRQ scores (LS means)
after 12 weeks of treatment (or early termination). FFIS:
formoterol fumarate inhalation solution 20 mg BID and FA:
formoterol fumarate DPI 12 mg BID. *pp0.03 vs placebo, (- - -):
clinically meaningful change.
Nebulized formoterol for COPD 193similar to those of FA. There were no statistically significant
differences between FFIS and FA for any pulmonary function
measurement at any time point at any visit.
Health-related quality of life
Subjects in the FFIS group experienced statistically sig-
nificant and clinically relevant improvements from baseline
in total SGRQ, symptom, and impact scores compared with
placebo (pp0.03; Figure 4). The LS mean differences
between FFIS and placebo were 4.91 for total score (95%
CI, 8.45 to 1.37, p ¼ 0.0067), 5.72 for symptom score
(95% CI, 10.87 to 0.57, p ¼ 0.0295), and 5.44 for
impacts score (95% CI, 9.44 to 1.44, p ¼ 0.0079) with
changes from baseline and differences from placebo above
the threshold for clinical significance (X4 units).17
FA-treated subjects demonstrated significant LS mean
differences from placebo only for symptom scores. There
were no statistically significant differences in total or
component scores between the FFIS and FA groups.
Rescue medication use
At baseline (screening to Day 1), subjects in all treatment
groups were treated with placebo and used similar amounts
of albuterol, approximately 2.7 puffs per day (Figure 5).
Albuterol use in the placebo group remained consistent
throughout the study; however, use of rescue medication
was reduced by 42% in the FFIS group during the firstassessment period and maintained throughout treatment.
From Weeks 8 to 12, the LS mean difference in daily
albuterol use between FFIS and placebo-treated subjects
ARTICLE IN PRESS










63 (51.2) 69 (60.5) 65 (57.0)
Most frequent adverse events
Headache 7 (5.7) 5 (4.4) 8 (7.0)
Nausea 6 (4.9) 4 (3.5) 3 (2.6)
Diarrhea 6 (4.9) 2 (1.8) 4 (3.5)
COPD exacerbation 5 (4.1) 7 (6.1) 9 (7.9)
Nasopharyngitis 4 (3.3) 2 (1.8) 2 (1.8)
Dry mouth 4 (3.3) 2 (1.8) 2 (1.8)
Dizziness 3 (2.4) 8 (7.0) 1 (0.9)
Dyspnea 3 (2.4) 3 (2.6) 4 (3.5)
Vomiting 3 (2.4) 2 (1.8) 2 (1.8)
Insomnia 3 (2.4) 0 0
Cough 2 (1.6) 5 (4.4) 5 (4.4)
Upper respiratory
tract infection
2 (1.6) 3 (2.6) 2 (1.8)
Urinary tract
infection
2 (1.6) 2 (1.8) 3 (2.6)
Sinusitis 0 4 (3.5) 2 (1.8)
Nasal congestion 2 (1.6) 0 3 (2.6)
Pain in extremity 1 (0.8) 3 (2.6) 1 (0.9)
Dyspnea exacerbation 0 3 (2.6) 0
Respiratory tract
congestion
0 0 3 (2.6)
Influenza 0 0 3 (2.6)
Skin infection 0 0 3 (2.6)
Frequency in any group X2%.
Figure 5 Mean daily albuterol use, puffs/day. FFIS: formoterol
fumarate inhalation solution 20 mg BID and FA: formoterol
fumarate DPI 12 mg BID. *pp0.0003 vs placebo.
N.J. Gross et al.194was 1.25 puffs (95% CI, 1.91 to 0.59, p ¼ 0.0002).
Results for the FA group were similar to those of the FFIS
group.
Adverse events
Over half of subjects reported at least one treatment-
emergent adverse event (TEAE); the overall incidence was
similar across treatment groups (Table 3). The incidence of
COPD exacerbation was higher in the placebo group (7.9%)
compared with the FFIS group (4.1%), a trend also seen for
other respiratory events such as dyspnea, cough, and
respiratory tract congestion. Also, differences were ob-
served between FFIS and FA groups, respectively, in the
rates of diarrhea (4.9% vs 1.8%), dizziness (2.4% vs 7.0%),
and cough (1.6% vs 4.4%). Most TEAEs were mild-to-
moderate in intensity. Overall, 16% of subjects experienced
X1 drug-related TEAE; the incidence was comparable
across treatment groups. Drug-related TEAEs experienced
by X1% of FFIS subjects and with a frequency greater
than placebo were dry mouth (2.4%), nausea (2.4%), and
insomnia (1.6%).
No deaths occurred during the double-blind period of the
study. Overall, 9/351 (2.6%) of the enrolled subjects
experienced a treatment–emergent serious adverse event
(SAE), 0.8%, 2.6%, and 4.4% in the FFIS, FA, and placebo
groups, respectively. COPD exacerbation was the only SAE
reported in more than one subject (two placebo-treated
subjects). No SAE was categorized by the study site
investigator as drug related. Discontinuations from the
study due to TEAEs occurred in 3.3%, 3.5%, and 8.8% in
the FFIS, FA, and placebo groups, respectively (Figure 1).
The only TEAE that led to discontinuation in41 subject was
COPD exacerbation.
Other safety evaluations
Laboratory evaluations for most chemistry, hematology, and
urinalysis parameters were within the normal range at
baseline and endpoint across subjects in all treatment
groups. Mean changes from screening were generally small
and comparable among treatment groups. Very few subjectshad clinically significant laboratory tests at the end of
treatment or clinically significant changes from baseline.
Mean serum glucose and potassium, analytes occasionally
affected by b2-agonist treatment,
18 were similar across
treatment groups; no formoterol-treated subject had a post-
treatment value or change from baseline of clinical
significance. Additional cardiovascular safety outcomes are
separately presented.19Discussion
In the current study, twice-daily nebulized formoterol
provided improvements in pulmonary function that were
comparable to DPI (Foradils 12 mg) and superior to placebo
in subjects with moderate-to-severe COPD. The results are
consistent with previously published studies with formoterol
DPI treatment,9–11 and are the first to directly demonstrate
comparable safety and efficacy of formoterol delivered by
two different methods and doses.
Significant onset of bronchodilation was observed at the
first spirometric timepoint (5min) and continued throughout
the 12 h of serial testing, relative to placebo. For the
primary endpoint, FEV1 AUC0–12, a statistically significant
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observed. No decline in FEV1 AUC0–12 was observed between
Day 1 and Week 12 in the FFIS-treated subjects. Similarly,
the peak FEV1, trough FEV1, and FVC were significantly
increased and maintained. The need for rescue medication
was reduced by regular maintenance therapy with formo-
terol to almost half the level observed in the placebo group.
Improvements in pulmonary function and rescue medication
use were sustained over the 12-week treatment period with
no evidence of tolerance/tachyphylaxis. In contrast, results
of a similar clinical study with a single enantiomer
formulation, arformoterol tartrate, suggested evidence of
tolerance within 6 weeks at all doses tested.20
In the current study, treatment with racemic formoterol
was well tolerated. Exacerbations of COPD, predefined and
classified as adverse events, were less frequent in the FFIS
group than the placebo group. With the exception of dry
mouth, nausea, and insomnia, FFIS-treated subjects did not
report increased drug-related TEAEs compared to those on
placebo. Rates of TEAEs in the FFIS group were also similar
to those in the FA group, with apparent differences in rates
of diarrhea, dizziness, and cough observed in this 12-week
study. The higher rates of diarrhea in the FFIS group and
dizziness in the FA group are similar to results from another
large 12-month open-label safety trial.21 In addition, results
of extensive cardiovascular safety monitoring in the
study, described in more detail in a separate publication,
revealed no clinically significant cardiovascular effects of
treatment.19
Nebulized COPD treatments are a medical necessity for
some patients. Evidence-based guidelines concluded that
there are no significant efficacy or safety differences among
aerosol delivery devices and selection should be based on
variables including preference, cost, setting, age and ability
to use the device, convenience, and, ultimately, compli-
ance.3 Patients consider nebulizers helpful in managing
COPD and maintaining well-being,1 and have reported
greater bronchodilatory improvement with nebulizer
therapy.22–24 Nebulized bronchodilators provide a needed
alternative for those many patients who are unable to use a
DPI or MDI for reasons including frailty, arthritis, visual
impairment, compromised mental capacity, exacerbation,
inability to understand how to use it, or inadequate hand/
breath coordination.25–27 In a trial of 316 asthma and COPD
patients, 88.9% failed to use their MDI or DPI correctly,28 and
another study reported that education failed to improve the
475% rate of inhaler misuse.29 Although breath-actuated
DPIs like FA have alleviated coordination difficulties, they
require a high peak inspiratory flow to disaggregate and
disperse the drug powder, which elderly COPD patients may
be unable to generate.26 In the current study, health status
was measured by SGRQ. FFIS treatment was associated with
statistically significant and clinically meaningful improve-
ments in total SGRQ score and its symptom and impact
components compared to placebo, while FA improved only
symptom scores. Others recently demonstrated superior
quality-of-life improvements for patients using a combina-
tion of daily nebulizer and MDI treatment over MDI alone.30
These results together suggest a possible quality-of-life
advantage of nebulized treatments over hand-held aerolized
delivery of the same medication. Studies using additional
patient-centered endpoints such as 6-min walk test andBDI/TDI are warranted to establish subjective and objective
benefits of nebulized formoterol.
Approximately 20% of study subjects used concomitant
ICS, which were permitted during the trial. The rate of ICS
use was similar across treatment groups in our study and
lower than in similar multicenter studies of formoterol in
COPD performed outside the United States.9,10 Cazzola
et al. reported that in a single-dose, double-blind crossover
study, the addition of ICS to formoterol influenced the onset
of bronchodilation, with significantly faster onset in respon-
sive subjects and greater improvement in FEV1.
31 Further
investigation to understand the potential influence of
concomitant ICS use on the efficacy and safety of nebulized
formoterol is warranted.
In conclusion, the current study demonstrated that twice-
daily nebulized formoterol is an effective and well-tolerated
alternative for maintenance treatment of moderate-to-
severe COPD. FFIS provided rapid and sustained improve-
ments in pulmonary function, quality of life and rescue
medication use.
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